Hazard ratios for breast cancer–specific mortality, stratified by race
| White (n = 631) | African American (n = 518) | |||
|---|---|---|---|---|
| HR adjusted for age at diagnosis and date of diagnosis (95% CI) | HR adjusted for age at diagnosis, date of diagnosis, and stage at diagnosis (95% CI) | HR adjusted for age at diagnosis and date of diagnosis (95% CI) | HR adjusted for age at diagnosis, date of diagnosis, and stage at diagnosis (95% CI) | |
| Menopausal status | ||||
| Premenopausal | 1.00 | 1.00 | 1.00 | 1.00 |
| Postmenopausal | 0.6 (0.3–1.0) | 0.6 (0.3–1.0) | 0.8 (0.5–1.3) | 0.8 (0.5–1.3) |
| Subtype | ||||
| Luminal A | 1.00 | 1.00 | 1.00 | 1.00 |
| Luminal B | 1.6 (0.9–2.9) | 1.5 (0.8–2.7) | 1.3 (0.6–2.4) | 1.2 (0.6–2.2) |
| Basal-like | 2.0 (1.2–3.4) | 1.7 (1.0–2.9) | 1.5 (1.0–2.4) | 1.4 (0.9–2.1) |
| HER2+/ER− | 2.4 (1.2–4.7) | 1.4 (0.7–2.9) | 2.3 (1.3–4.0) | 1.8 (1.0–3.1) |
| Unclassified | 1.6 (0.9–3.1) | 1.6 (0.9–3.1) | 1.3 (0.8–2.3) | 1.2 (0.7–2.0) |
| Subtype combined | ||||
| Luminal A or B | 1.00 | 1.00 | 1.00 | 1.00 |
| Basal-like | 1.8 (1.1–3.0) | 1.6 (0.9–2.6) | 1.5 (1.0–2.2) | 1.3 (0.9–2.0) |
| HER2+/ER− | 2.1 (1.1–4.2) | 1.3 (0.6–2.6) | 2.2 (1.3–3.7) | 1.7 (1.0–2.9) |
| ER status | ||||
| ER+ | 1.00 | 1.00 | 1.00 | 1.00 |
| ER− | 1.5 (1.0–2.2) | 1.3 (0.9–1.9) | 1.7 (1.2–2.5) | 1.5 (1.0–2.2) |
| PR status | ||||
| PR+ | 1.00 | 1.00 | 1.00 | 1.00 |
| PR− | 1.8 (1.2–2.7) | 1.6 (1.1–2.4) | 1.6 (1.1–2.3) | 1.4 (0.9–2.0) |
| HER2 status | ||||
| HER2− | 1.00 | 1.00 | 1.00 | 1.00 |
| HER2+ | 1.5 (0.9–2.3) | 1.2 (0.7–1.9) | 1.4 (0.9–2.2) | 1.3 (0.8–1.9) |